Core Viewpoint - Despite fluctuations in the A-share market and adjustments in the pharmaceutical sector, overall market sentiment remains active, with the pharmaceutical sector showing resilience and growth potential due to various catalytic events [1] Industry Insights - The upcoming ESMO conference in October is expected to release new research findings that could enhance the international competitiveness of Chinese innovative drugs [1] - The pharmaceutical sector is anticipated to experience a value reassessment, driven by strong performance and overseas expansion potential of innovative drugs [1] - The National Healthcare Security Administration emphasized the importance of balancing quality and price in drug procurement, indicating a focus on quality in the pharmaceutical industry [1] - The Ministry of Industry and Information Technology held a meeting to strengthen the innovation capabilities of pharmaceutical companies and promote AI integration across the entire pharmaceutical industry chain [1] Fund Management Insights - Zhongyin Fund has multiple pharmaceutical-themed funds managed by a skilled team, with a focus on long-term pricing and filtering out short-term noise to assess long-term value [1][2] - Fund manager Zheng Ning emphasizes a risk-reward balance rather than short-term performance rankings, aiming for consistent returns across market cycles [2] - Zheng Ning's funds have performed well, with Zhongyin Innovation Medical A ranking in the top five of its category over the past year, and other funds also showing strong performance in their respective categories [2] Performance Review - Zhongyin Hong Kong Stock Connect Medical A, managed by Zheng Ning since December 29, 2023, reported a net value growth rate of -11.60% for 2024 and 70.08% for the first half of 2025 [5] - Zhongyin Innovation Medical Mixed A, managed since July 1, 2022, showed a net value growth rate of 54.08% for the first half of 2025 [6] - Zhongyin Healthcare Mixed A, managed since October 13, 2022, reported a net value growth rate of 51.59% for the first half of 2025 [7]

Core Viewpoint - The pharmaceutical sector in the A-share market has shown structural performance, with the innovative drug index rising by 60.77% year-to-date, significantly outperforming the overall A-share index by 22.14% [1] Group 1: Pharmaceutical Sector Performance - The pharmaceutical sector has been active this year, with innovative drug indices leading the gains [1] - The performance of pharmaceutical-themed mutual funds has attracted investor attention, with notable returns reported [1] - Zhongyin Fund's pharmaceutical-themed funds have ranked well among peers, with Zhongyin Innovation Medical A achieving top rankings over various time frames [1] Group 2: Fund Manager Insights - Fund manager Zheng Ning employs a long-term pricing focus, filtering out market noise to concentrate on long-term implied returns [3] - The performance of Zhongyin Hong Kong Stock Connect Pharmaceutical A has shown significant growth, with a net value growth rate of 70.08% in the first half of 2025 [3] - Zheng Ning has managed multiple funds, consistently achieving competitive returns compared to benchmarks [4][6] Group 3: Market Drivers - The recent rise in the innovative drug sector is driven by fundamental improvements, including advancements in R&D, successful profit realization, and favorable policies [2] - The innovative drug industry is expected to have substantial growth potential, becoming a strategic industry in China's export structure and a key pillar in the global pharmaceutical industry [2]

Group 1 - The pharmaceutical sector continues to rise, boosting the performance of funds heavily invested in this industry, with many public FOFs ranking high in weekly returns [1][2] - There is a division in the industry regarding the sustainability of this rally, with some optimistic about the revaluation of pharmaceutical stocks, while others remain cautious about the end of short-selling [1][4] - Long-term prospects are bolstered by the increasing international competitiveness of domestic innovative drugs, which continues to attract capital from both domestic and foreign investors [1][4] Group 2 - Recent statistics show significant gains in pharmaceutical-themed funds, with some achieving over 60% returns year-to-date, similar to previous trends seen in AI concept stocks [2][4] - The top-performing mixed FOF last week, Guotai Youxuan Lihang, reported a weekly return of 4.56%, largely due to its holdings in pharmaceutical funds [2][3] - The healthcare sector's performance is supported by a reversal in profit margins for the first quarter of 2025, marking the first signs of recovery after three years of declining profitability [4] Group 3 - The influx of capital into the pharmaceutical sector has been significant, with over 20 billion yuan net inflow this year, particularly into innovative drugs and medical devices [4][5] - The current market sentiment is driven by high elasticity sectors such as new consumption and innovative drugs, which are expected to continue performing well [3][5] - Institutional interest in the pharmaceutical industry is increasing, with a notable rise in research and analysis activity, indicating a potential for sustained recovery and structural opportunities [5]